Session » Abstracts: SpA Including PsA – Treatment I
- 3:00PM-4:30PM
-
Abstract Number: 1760
A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Mitogen-activated Protein Kinase-Activated Protein Kinase 2 (MK2) Inhibitor in Active Ankylosing Spondylitis
- 3:00PM-4:30PM
-
Abstract Number: 1757
Bimekizumab Treatment Resulted in Improvements in MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: 52-Week Results and Post Hoc Analyses from Two Phase 3 Studies
- 3:00PM-4:30PM
-
Abstract Number: 1758
Minimal Spinal Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis over 2 Years of Bimekizumab Treatment: Results from a Phase 3 Open-Label Extension Study
- 3:00PM-4:30PM
-
Abstract Number: 1759
Predictors of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis Receiving IL-17A Inhibitor or TNF Inhibitor Therapy over 2 Years: A Post Hoc Analysis of a Phase IIIb Study
- 3:00PM-4:30PM
-
Abstract Number: 1755
Single Cell TCR Sequencing Suggests Potential Limitations of TRBV9-depleting Therapies in Axial Spondyloarthritis
- 3:00PM-4:30PM
-
Abstract Number: 1756
What Is the Impact of Prior TNF Inhibitor Treatment on the Time to Achieve Low Disease Activity and the Durability of Low Disease Activity? Real-world Results Based on 17 858 European Patients with Axial Spondyloarthritis Initiating a TNF Inhibitor or an IL-17A Inhibitor